Vaccine News and Research

Latest Vaccine News and Research

HPV-positive tumor status is strong prognostic factor for head, neck cancer

Oropharyngeal cancer patients whose tumors in the upper part of the throat test positively for the human papillomavirus (HPV) have better overall survival than patients with HPV-negative disease, researchers from The University of Texas MD Anderson Cancer Center report in a study published in The New England Journal of Medicine.

8 Jun 2010

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

8 Jun 2010

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.

8 Jun 2010

Updated HIV treatment guidelines may benefit individuals infected with HIV: Researchers

Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.

8 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Melinda Gates today urged global leaders to make women's and children's health a top priority, and announced that the Gates Foundation will invest $1.5 billion over the next five years to support maternal and child health, family planning, and nutrition programs in developing countries.

8 Jun 2010

Sentrx achieves Gold Partner status in OPN

Sentrx, a leading provider of drug safety services to the life sciences industry, has achieved Gold Partner status in the Oracle PartnerNetwork. Sentrx will provide life sciences companies with support for Oracle clinical solutions, emphasizing its expertise in drug safety systems, safety data management and adverse event reporting software, processes and consulting expertise.

7 Jun 2010

Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting

Celldex Therapeutics, Inc. today announced the presentation of promising clinical data on CDX-011 in metastatic melanoma at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The Phase 2 study has met its primary endpoint and the results support additional studies in this indication.

7 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.

7 Jun 2010

Ipilimumab extends survival of metastatic melanoma patients: Study

A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study's researchers will report their findings simultaneously at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and in the New England Journal of Medicine.

7 Jun 2010

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

7 Jun 2010

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a potentially longer disease-free survival and one-year overall survival in this patient group than reported in previous studies of surgery and adjuvant therapy alone. These data were presented in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago (Abstract #8588).

5 Jun 2010

BMJ report questions WHO advisors' ties to pharmaceutical industry

"Key scientists behind World Health Organization advice on stockpiling of pandemic flu drugs had financial ties with companies which stood to profit," according to a joint investigation by BMJ in collaboration with the Bureau of Investigative Journalism, BBC News reports (6/4).

5 Jun 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, today announces a strategic collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc.. Under the agreement, Scancell and ImmuneRegen will work together to investigate the synergy between ImmuneRegen's Homspera® and Scancell's ImmunoBody® vaccine technologies.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

HPV-positive tumor status is strong prognostic factor for head, neck cancer

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Updated HIV treatment guidelines may benefit individuals infected with HIV: Researchers

Research findings open door to development of new therapies for lymphomas, leukemias

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Sentrx achieves Gold Partner status in OPN

Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Ipilimumab extends survival of metastatic melanoma patients: Study

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

High IL-10 levels in tumor cells may decrease effectiveness of autologous melanoma vaccine: Study

BMJ report questions WHO advisors' ties to pharmaceutical industry

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Scancell's ImmunoBody vaccine technologies to be combined with ImmuneRegen's Homspera

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in